文献速递冠心病血脂与心血管预防

血小板反应性指导ACS患者等待CABG手术的抗血小板策略

Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该随机开放标签非劣效试验纳入190例接受阿司匹林和P2Y12抑制剂、有CABG指征的ACS患者,比较血小板反应性指导策略(监测Multiplate直至≥46聚集单位后次日手术)与标准治疗(术前5-7天停用P2Y12抑制剂)。结果显示两组CABG后24小时出血非劣效,干预组等待时间显著缩短且住院费用降低。

要点

  • 血小板反应性指导策略在CABG后24小时出血方面非劣效于标准治疗。
  • 该策略显著缩短从决定CABG到手术的等待时间。
  • 干预组住院费用中位数降低,意向治疗分析降6.4%。

核心结论

  • 基于血小板反应性指导的策略在ACS等待CABG患者中围术期出血非劣效于标准治疗,显著缩短等待时间并降低住院费用。

研究设计与样本

  • 随机、开放标签、非劣效试验,纳入190例因ACS入院、有CABG指征且正在使用阿司匹林和P2Y12受体抑制剂的患者。

主要发现

  • CABG后24小时内,干预组和对照组中位胸管引流量分别为350 ml(IQR 250-475 ml)和350 ml(IQR 255-500 ml),非劣效性p<0.001。
  • 从决定CABG到手术的中位等待时间干预组为112小时(IQR 66-142 h),对照组为136小时(IQR 112-161 h),p<0.001。
  • 意向治疗分析中干预组住院费用中位数降低6.4%(p=0.014),符合方案分析降低11.2%(p=0.003)。

关键数值与推荐

  • 干预组每日用Multiplate分析仪测量血小板反应性,血小板反应性恢复至预设阈值≥46聚集单位后安排下一工作日行CABG。
  • 对照组在CABG前5至7天停用P2Y12受体抑制剂。

临床怎么用

  • 对于ACS后需CABG且正在使用P2Y12抑制剂的患者,可考虑采用血小板反应性监测指导手术时机,以缩短等待时间并可能降低住院费用。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy is recommended for patients with acute coronary syndromes (ACS). Approximately 10% to 15% of these patients will undergo coronary artery bypass graft (CABG) surgery for index events, and current guidelines recommend stopping clopidogrel at least 5 days before CABG. This waiting time has clinical and economic implications. OBJECTIVES: This study aimed to evaluate if a platelet reactivity-based strategy is noninferior to standard of care for 24-h post-CABG bleeding. METHODS: In this randomized, open label noninferiority trial, 190 patients admitted with ACS with indications for CABG and on aspirin and P2Y12 receptor inhibitors, were assigned to either control group, P2Y12 receptor inhibitor withdrawn 5 to 7 days before CABG, or intervention group, daily measurements of platelet reactivity by Multiplate analyzer (Roche Diagnostics GmbH, Vienna, Austria) with CABG planned the next working day after platelet reactivity normalization (pre-defined as ≥46 aggregation units). RESULTS: Within the first 24 h of CABG, the median chest tube drainage was 350 ml (interquartile range [IQR]: 250 to 475 ml) and 350 ml (IQR: 255 to 500 ml) in the intervention and control groups, respectively (p for noninferiority <0.001). The median waiting period between the decision to undergo CABG and the procedure was 112 h (IQR: 66 to 142 h) and 136 h (IQR: 112 to 161 h) (p < 0.001), respectively. In the intention-to-treat analysis, a 6.4% decrease in the median in-hospital expenses was observed in the intervention group (p = 0.014), with 11.2% decrease in the analysis per protocol (p = 0.003). CONCLUSIONS: A strategy based on platelet reactivity-guided is noninferior to the standard of care in patients with ACS awaiting CABG regarding peri-operative bleeding, significantly shortens the waiting time to CABG, and decreases hospital expenses. (Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT; NCT02516267).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nakashima CAK, Dallan LAO, Lisboa LAF, et al. Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization. J Am Coll Cardiol. 2021. PMID: 33706868. doi:10.1016/j.jacc.2021.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。